Table 1 Baseline characteristics of HIV-2-infected Senegalese adults participating in a drug resistance-based algorithmic ART switching study
All participants (n=152) | |
|---|---|
Female, number (%) | 123 (80.1%) |
Age (years), median (IQR) | 55 (48–62) |
HIV diagnosis year, median (range) | 2012 (1995–2019) |
ART initiation year, median (range) | 2013 (2001–2020) |
WHO clinical stage, number (%) | |
1 | 43 (28.5%) |
2 | 30 (19.9%) |
3 | 67 (44.4%) |
4 | 11 (7.3%) |
BMI category, number (%) | |
Underweight/malnourished (<18.5) | 22 (14.5%) |
Normal weight (18.5-24.9) | 68 (44.8%) |
Overweight (25.0-29.9) | 41 (27.0%) |
Obese (30+) | 21 (13.8%) |
Participants initiating ART, number (%) | 10 (6.6%) |
CD4 counta (cells/μL), median (IQR) | 332 (173–552) |
Plasma viral loadb < 50 copies/mL, number (%) | 4 (66.7%) |
Plasma viral loadc, log10 copies/mL, median (IQR) | 1.15 (1.11–2.18) |
ART-experienced participants, number (%) | 142 (93.4%) |
CD4 counta (cells/μL), median (IQR) | 578 (359–847) |
Plasma viral loadb < 50 copies/mL, number (%) | 101 (91.0%) |
Plasma viral loadc, log10 copies/mL, median (IQR) | 1.18 (0.90–2.12) |
Baseline ARV regimen | |
LPV/r-AZT-3TC | 68 (44.7%) |
LPV/r-TDF-3TC | 84 (55.3%) |